Chemomab Therapeutics (NASDAQ:CMMB) Shares Up 1.3% – Should You Buy?

Chemomab Therapeutics Ltd. Sponsored ADR (NASDAQ:CMMB)’s share price shot up 1.3% on Friday . The stock traded as high as $1.58 and last traded at $1.55. 29,971 shares were traded during trading, a decline of 87% from the average daily volume of 235,683 shares. The stock had previously closed at $1.53.

Analysts Set New Price Targets

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Chemomab Therapeutics in a research note on Friday, May 8th. One analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, Chemomab Therapeutics has a consensus rating of “Hold” and an average price target of $25.00.

Chemomab Therapeutics Stock Up 1.3%

The stock’s 50 day moving average is $1.72 and its two-hundred day moving average is $1.69. The company has a market capitalization of $11.16 million, a PE ratio of -0.70 and a beta of 0.64.

Chemomab Therapeutics (NASDAQ:CMMB) last posted its earnings results on Thursday, May 14th. The company reported ($0.22) EPS for the quarter, missing analysts’ consensus estimates of ($0.04) by ($0.18). On average, sell-side analysts predict that Chemomab Therapeutics Ltd. Sponsored ADR will post -0.4 EPS for the current fiscal year.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the stock. ADAR1 Capital Management LLC purchased a new stake in shares of Chemomab Therapeutics during the 4th quarter worth $132,000. Kestra Private Wealth Services LLC grew its stake in Chemomab Therapeutics by 19.3% in the first quarter. Kestra Private Wealth Services LLC now owns 61,710 shares of the company’s stock valued at $97,000 after purchasing an additional 10,000 shares during the last quarter. Finally, XTX Topco Ltd purchased a new position in Chemomab Therapeutics in the fourth quarter valued at about $31,000. 46.05% of the stock is owned by institutional investors.

Chemomab Therapeutics Company Profile

Chemomab Therapeutics (NASDAQ:CMMB) is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of next-generation antibody therapies. The company leverages a proprietary antibody engineering platform to generate novel bi- and multi-specific antibodies with applications in oncology, infectious diseases and inflammatory disorders. By combining cutting-edge discovery tools with translational research, Chemomab aims to advance promising candidates from early proof-of-concept through clinical development.

Among its pipeline programs, Chemomab is advancing antibody candidates designed to target key tumor antigens and pathogen-specific epitopes.